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sitive in vitro ﬁndings for cosmetic ingredients. Due to the 7th
amendment to the EU Cosmetics Directive testing ban (EU, 2003)
that was enacted March 2009, it is no longer possible to conduct fol-
low-up in vivo genotoxicity in this area. To address this, a workshop
of COLIPA (The European Cosmetics Association) Safety Assessment
and Genotoxicity project teams was held in Brussels on 3rd April
2008. Participants included members from a number of global cos-
metic companies. The aim of the meeting was to (a) discuss company
perspectives and current practices for the safety assessment of geno-
toxicity of cosmetic ingredients and (b) design a decision tree ap-
proach to the safety assessment of their potential to cause
genotoxicity, with emphasis on non-animal methods. The outcome
of this meeting is reported herein, starting with a review of the spe-
ciﬁc scientiﬁc challenges related to in vitro testing and the impact of
the 7th Amendment. We describe research projects that have been
undertaken by the COLIPA Genotoxicity Project Team to address
the major limitations of the current in vitro testing paradigm. A pro-
posed strategy is provided for the use of the non-animal methods to
enable a thorough assessment of the genotoxic hazard of cosmetic
ingredients.2. Genotoxicity testing of cosmetic ingredients – challenges and
approaches
2.1. In vitro genotoxicity testing leads to high percentage of misleading
positive results
Due to the diverse nature of the mechanisms involved in geno-
toxicity, it is known that no single mutagenicity test can detect all
classes and examples of genotoxic carcinogens. As a result, interna-
tional guidelines for assessing the genotoxic potential of chemicals
recommend the use of a battery of mutagenicity tests to detectTable 1
A comparison of the sensitivity and speciﬁcity of some of the in vitro genotoxicity assays
Test OECD TG Sens
carci
Bacterial reverse mutation test, Ames test 471a 58.8
45
54
49.4
In vitro micronucleus test (MNT) Draft 487b 78.7
87.3
89.2
In vitro mammalian cell gene mutation test
Mouse lymphoma assay (MLA) and hypoxanthine–guanine
phosphoribosyl transferase (HPRT) test
476c MLA
73.1
70.9
62.8,
HPRT
48.4
In vitro mammalian chromosomal aberration assay 473d 65.6
55.3
Ames + MNT 85.9
Ames + CA 75.3
Ames + MLA + MNT 90.7
Ames + MLA + CA 84.7
In vitro Syrian hamster embryo (SHE) cell transformation assay Draft 495e 87
66
92
a OECD TG 471 (1997).
b OECD TG 487 (2009).
c OECD TG 476 (1997).
d OECD TG 473 (1997).
e OECD TG 495.gene, chromosome or genome mutations (Eastmond et al., 2009;
Regulation, Evaluation, Authorisation of Chemicals (REACh); Inter-
national Conference on Harmonisation (ICH), 2008; SCCP, 2006a,b,
COM, 2000). For cosmetic ingredients, the Scientiﬁc Committee on
Consumer Safety (SCCS, formerly the Scientiﬁc committee on Con-
sumer Products (SCCP)) is the expert panel mandated by the Euro-
pean Commission to develop opinions for testing, review dossier
submissions, and provide opinions concerning all types of safety
risks. The SCCS recommended basic test battery for testing cos-
metic ingredients for their genotoxic potential is: (1) two tests
for gene mutation, the bacterial reverse mutation or ‘‘Ames” test
(Organisation for Economic Co-operation and Development Test
Guidelines (OECD TG) 471, 1997) and an in vitro gene mutation as-
say in mammalian cells (OECD TG 476, 1997) and (2) a test for clas-
togenicity and aneugenicity using the in vitro micronucleus test
(MNT) (OECD TG 487, in development) (SCCP, 2006a,b). If all these
tests are negative then no further testing is required.
The sensitivity and speciﬁcity of a number of in vitro genotoxi-
city assays in terms of predicting rodent carcinogenicity are shown
in Table 1. Kirkland et al. (2005a, 2006) evaluated the predictivity
of four standard in vitro tests for rodent carcinogenicity. The sensi-
tivity of the MNT (i.e. ability to give positive results with rodent
carcinogens) was the highest of the four individual tests analysed
(though the database was smaller than the other assays) and the
addition of the Ames assay increased the sensitivity further. For
example, the sensitivity of the Ames assay was increased from
58.8% to 85.9% and 75.3% when it was combined with the mouse
lymphoma assay (MLA), MNT or CA assay, respectively. Unfortu-
nately, the speciﬁcity (the ability to correctly identify non-carcino-
gens) is greatly decreased with the addition of in vitro tests in a
battery. For instance, the speciﬁcity of the Ames assay ranges from
74% to 80% (Table 1) and combining the Ames test with two other
tests as required in the SCCS battery decreases the speciﬁcity to a
low as 5–23% (Table 1). It is important to note that for some chem-currently available. Taken from Kirkland et al., 2005b.
itivity to rodent
nogens (%)
Speciﬁcity to rodent
carcinogens (%)
Reference
73.9 Kirkland et al. (2005a)
Tennant et al. (1987)
Zeiger (1998)
80.3 Matthews et al. (2006)
30.8 Kirkland et al. (2005a)
23.1 Matthews et al. (2006)
55.0 Corvi et al. (2008)
/TK: MLA/TK:
39.0 Kirkland et al. (2005a)
57.8 Zeiger (1998)
70.9 44.2 Matthews et al. (2006)
/CHO:
65.2 Matthews et al., 2006
44.9 Kirkland et al. (2005a)
63.3 Matthews et al. (2006)
121.0 Kirkland et al. (2005a)
34.6 Kirkland et al. (2005a)
5.0 Kirkland et al. (2005a)
22.9 Kirkland et al. (2005a)
83 LeBoeuf et al. (1996) (24 h and 7 day)
85 OECD DRP (pH 6.7; 7 day only)
66 OECD DRP (pH 7.0; 7 day only)
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speciﬁcity of the standard in vitro genotoxicity tests is even lower,
rendering them essentially uninformative. For instance, speciﬁcity
for rodent non-carcinogenic aromatic amines in the Ames assay is
only 29% (Ashby and Tennant, 1991), indicating 71% misleading
positives (MPs) in this single assay. Combining the Ames assay
with other in vitromammalian cell assays for aromatic amines will
therefore result in almost all of these chemicals yielding a positive
result in one or more assays.
Clearly, protection of consumers by employing sensitive tests to
evaluate the potential genotoxicity of compounds is paramount,
but the use of tests with such low speciﬁcities means that unac-
ceptably high numbers of MPs are generated. This leads (for cos-
metic ingredients: did lead before March 2009) to the necessity
to conduct numerous in vivo genotoxicity assays, as well as mech-
anistic studies, and complex risk assessments. The complexity of
risk assessments for compounds positive in standard in vitro geno-
toxicity assays is illustrated by the many recent publications (e.g.
Elespuru et al., 2009; Eastmond et al., 2009), external workgroups,
and meetings devoted to this topic. MP in vitro results will not only
trigger (for cosmetic ingredients: have triggered) the use of large
numbers of animals, but also require extensive time and personnel
within regulatory agencies as well as industry. Because of the enor-
mous resources involved in clarifying positive results from stan-
dard in vitro testing, cosmetic companies often eliminate such
ingredients from use, thereby losing potentially safe and useful
ingredients.
2.2. Impact of the Cosmetics Directive
The 7th Amendment to the Cosmetics Directive (EU, 2003)
banned in vivo genotoxicity assays for cosmetic ingredients as of
March 2009, and the performance of repeated dose toxicity (RDT)
tests by March 2013. Therefore, the standard approach in all test-
ing strategies of conducting in vivo genotoxicity assays as a fol-
low-up for in vitro genotoxins is no longer possible for these
chemicals. This lack of in vivo follow-up options is considered to
have a negative impact on the evaluation of the mutagenic poten-
tial of cosmetic ingredients (Speit, 2009); the author concludes
that in many cases such an evaluation will be impossible. Likewise,
the SCCP issued an ofﬁcial opinion statement in January 2009
‘‘Consequently, after 11 March 2009, in many cases, it will not be
possible to evaluate the mutagenic potential of cosmetic ingredi-
ents on a sound scientiﬁc basis. Because the potential mutagenicity
of these ingredients is of major concern, an important part of the
toxicological evaluation of cosmetic ingredients cannot be accom-
plished” (SCCP, 2009). In addition, the conduct of in vivo genotox-
icity assays is not compatible with the general direction within the
scientiﬁc community to reduce animal testing and with large scale
programs such as REACh (European Commission, 2006). Tens ofTable 2
Explanations for ‘‘misleading negative” and ‘‘misleading positive” results in in vitro assays
Biological reasons for misleading results in vitro
Misleading
negatives
Epigenetic mode of action
Relevant genetic endpoint not measured (e.g. aneuploidy, and s
Differences in metabolic activation in vitro/in vivo
Organ speciﬁc compounds (in vivo)
Very reactive (short lived) compounds
Toxic compounds
Misleading
positives
The test compound will not react with DNA in vivo (e.g. not ab
reactive)
Differences in metabolic activation
Defence mechanism in vivo (e.g. detoxiﬁcation, repair, apoptosithousands of chemicals will need to be evaluated or re-evaluated
for their toxicological properties in this program, and in vivo fol-
low-up testing will be required for all chemicals that show positive
effects in any of the three standard in vitro genotoxicity assays, as
described in the endpoint speciﬁc guidance of the REACh Informa-
tion Requirements (European Chemicals Agency, 2008). Not only is
there a focused effort to reduce animal use and improve the perfor-
mance of the existing in vitro tests and/or to develop new in vitro
assays with better speciﬁcities for cosmetics in Europe (Tweats
et al., 2007), there is also a global need across many product cate-
gories for improved non-animal genotoxicity testing approaches
and ways to reduce animal use (Pfuhler et al., 2009).
2.3. The COLIPA genotoxicity program – towards improved in vitro
capabilities
To address the challenges created by the 7th Amendment to the
Cosmetics Directive (EU, 2003) ban on in vivo genotoxicity assays
for cosmetic ingredients, a COLIPA Genotoxicity Project Team
was established in 2004. The team conducted a review of factors
that inﬂuence the generation of MPs in the standard genotoxicity
assays (Kirkland et al., 2007a; see Table 2). This review, together
with the outcome of a workshop at European Centre for the Valida-
tion of Alternative Methods (ECVAM) held in 2006 (Kirkland et al.,
2007b), triggered the start of two COLIPA projects. The ﬁrst project
aims at improving existing in vitro standard genotoxicity tests to
avoid or minimise generation of MPs, while the second project fo-
cuses on the development of new assays that may allow follow-up
of positive results from standard genotoxicity testing.
2.3.1. Reduction of ‘‘false positive” results
The ﬁrst project is entitled ‘‘Reduction in the ‘‘false positive”
rate of in vitromammalian cell genotoxicity assays” and is co-spon-
sored by ECVAM and The National Centre for the Replacement,
Reﬁnement and Reduction of Animals in Research (UK NC3Rs).
The main areas of focus are:
(a) The use of cell types with higher relevance:
The effects of the cell type on the outcome of the MNT are
being studied to determine if there are cell lines which are
less susceptible to produce MPs. Cell lines that do not have
a high metabolic capacity (especially phase II enzymes)
may lack the ability to detoxify chemicals, thereby causing
MPs or ‘‘false positives”. Moreover, cell lines that are not
p53 competent or have a low proﬁciency in repairing DNA
(Chaung et al., 1997; Oka et al., 2006) are considered to be
hypersensitive and do not reﬂect the behaviour of normal
mammalian cells where DNA damage might either be
repaired or lead to apoptosis (Kirkland et al., 2007b). In the
project that started in October 2007 and is performed at.
Technical reasons for misleading results in vitro
Inadequate test conditions (e.g. concentration, pH, solubility,
stability)
ome CA) Volatile compounds
sorbed, very Contaminated test agent (bacterial tests)
Chemical impurities in test agent
Inadequate test conditions (e.g. concentration, pH)
s) Unstable in media, causing production of hydrogen peroxide
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cell lines (Chinese hamster ovary (CHO), Chinese hamster
lung (CHL and V79) cells) are compared with primary
human lymphocytes, the human lymphoblastoid cell line,
TK6, and the human hepatocellular carcinoma cell line,
HepG2, which has been shown to have similar drug meta-
bolising enzyme activities to those in primary human hepa-
tocytes (Hewitt and Hewitt, 2004; Westerink and Schoonen,
2007). The initial results of the COLIPA project show that
human cells (primary human lymphocytes and TK6, and
HepG2) appear to have better speciﬁcity than hamster cell
lines (Fowler et al., 2009, 2010).
(b) Consideration of measures of toxicity:
There has been debate for some time over the appropriate
measures of toxicity to be used in the mammalian cell
assays. It is long known that excessive cytotoxicity can cause
a positive result in genotoxicity testing which may not be
biologically relevant (Hilliard et al., 1998; Scott et al.,
1991; Kirkland, 1992; Greenwood et al., 2004). In particular,
the methods to determine cytotoxicity are known to have an
impact on the selection of the highest test concentration and
thus on the genotoxicity outcome (Hilliard et al., 2007), and
this topic has recently been discussed intensively in con-
junction with the adoption of the OECD TG 487 MNT guide-
line (Lorge et al., 2008; Fellows et al., 2008). Experimental
data from the COLIPA project indicate that toxicity measures
that determine cell proliferation should be preferred over
methods that do not consider this aspect (e.g. relative cell
count) as they are less likely to generate MPs (Williams
et al., 2009).
(c) Maximum concentration to be tested:
Concentrations of 10 mM in mammalian cell tests, as recom-
mended in guidelines, may well be in excess of the physio-
logically-relevant concentrations (Kirkland et al., 2007b).
Moreover, testing very high concentrations of chemicals in
the presence of rat liver S9 may lead to ‘‘inappropriate”
metabolism as such concentrations may far exceed the KM
of enzymes involved in their metabolism (e.g. the KM for
phenacetin metabolism by CYP1A2 is only 9 lM (Tass-
aneeyakul et al., 1993)). For this reason the revised draft
guideline of the ICH S2 (R1) limits the highest concentration
of pharmaceuticals to be tested for genotoxicity in vitro to
0.5 mg/mL or 1.0 mM, whichever is lower. The COLIPA ‘‘false
positives” project will compare the dose–response of
approximately 20 genotoxic carcinogens with a similar
number of MPs and may therefore help to decide which
impact the reduction of the maximum test concentration
may have on the sensitivity and speciﬁcity of in vitro assays
using mammalian cells. In addition, analysis of the maxi-
mum concentrations required in mammalian cell tests to
give positive results with rodent carcinogens that are nega-
tive in the Ames test has indicated that substantial reduction
from 10 mM can be achieved without losing sensitivity
(Parry et al., 2010; Kirkland and Fowler, 2010)
2.3.2. 3D human reconstructed human skin models for genotoxicity
testing
The second pillar of the COLIPA program is the development of
new assays that may allow the follow-up of positive results from
in vitro assays. Most cosmetic products, as well as many other
types of products/chemicals, are exclusively or predominantly in
contact with the skin; therefore, the skin will usually be the organ
with the highest potential exposure. Moreover, the skin is an effec-
tive barrier to chemicals (Potts et al., 1992) and metabolically ac-
tive (Oesch et al., 2007; Eilstein et al., 2009) such that
compounds applied to the skin may not enter the systemic circula-tion, or are detoxiﬁed prior to systemic circulation. Based on this,
assays using 3D human reconstructed skin (RS) models offer the
potential for a more physiologically relevant approach to test der-
mal exposure. RS models are prepared from primary human cells
and are expected to have normal DNA repair and cell cycle control.
They are also expected to exhibit a human metabolic capability
that is more relevant than the exogenous rodent metabolizing en-
zymes currently used in standard in vitro genotoxicity assays. Sim-
ilar xenobiotic metabolism gene expression in EpiSkin™ (Luu-The
et al., 2009) and EpiDerm™ (Hu et al., 2009a) to human skin has
been reported. It has also recently been shown that in EpiDerm™
and EpiSkin™ tissues, the aromatic amines, p-phenylenediamine
and p-aminophenol, are detoxiﬁed by N-acetylation in a similar
manner to human skin (Hu et al., 2009a,b; Nohynek et al., 2005).
RS models are now being used to develop two different tests for
in vitro genotoxicity:
(a) The RS micronucleus test (RSMN) (Curren et al., 2006; Mun
et al., 2009; Hu et al., 2009a,b). The intra- and inter-laboratory
reproducibility of the RSMN in EpiDermTM was reported by Hu
et al. (2009a,b) and Mun et al. (2009). In these studies, a number
of chemicals were evaluated (including model genotoxins which
exhibit a range of genotoxic mechanisms e.g. cross-linking (mito-
mycin C), alkylation (methyl methanesulfonate) and aneuploidy
(vinblastine) and the ability of this model to respond to different
types of genetic damage was ascertained. Moreover, dermal non-
carcinogens were determined to be negative, showing that the as-
say seems to have good speciﬁcity as well as sensitivity. This was
of particular importance because three of these substances (4-
nitrophenol, trichloroethylene and 2-ethyl-1,3-hexanediol) were
shown to be positive in one or more other in vitro genotoxicity
models (Mun et al., 2009). There was a good reproducibility be-
tween different tissue constructs containing keratinocytes isolated
from human foreskin tissue from four different donors (http://
www.mattek.com) of the EpiDerm™ model, which is important
since these primary cells have a ﬁnite lifespan and must be re-
placed by a new donor when batches of cells are depleted. Initial
results with chemicals that require metabolism are promising (Kal-
uzhny et al., 2009). Thus, the 3D skin tissue used in the RSMN re-
ﬂects exposure conditions of dermally applied cosmetic
ingredients allowing for more realistic exposure conditions and
hopefully better predictive performance.
(b) The RS Comet assay. The Comet assay detects a broad spec-
trum of DNA damage, including such that leads to gene mutation
(Hartmann et al., 2003). This fact is underlined by the high sensi-
tivity of the in vivo Comet assay for carcinogens with a gene muta-
tion signature, which it detects more efﬁciently than other assays
like transgenic mutation (TG) or unscheduled DNA synthesis
(UDS) (Kirkland and Speit, 2008). It therefore seems well suited
as additional endpoint to be incorporated into RS models. Initial re-
sults generated with this assay using several standard mutagens
are very promising (Flamand et al., 2006; Zeller et al., 2007).
To extend supporting data, a COLIPA project entitled ‘‘Develop-
ment of genotoxicity assays in 3D human skin models”, co-spon-
sored by ECVAM, on the validation of genotoxicity assays in RS
models was initiated in 2007. This project follows a modular vali-
dation approach (Hartung et al., 2004) and is divided into three
phases: Phase 1 – transferability, optimization, and within labora-
tory reproducibility with two model genotoxins; Phase 2 – be-
tween laboratory reproducibility with three coded chemicals and
Phase 3 – increasing domain of chemicals tested for predictive
capacity and further evaluation or reproducibility. To date, the
RSMN and the RS Comet assay using EpiDerm™ have been trans-
ferred to other US and European laboratories and the protocols
were harmonized as part of the COLIPA project. The RS Comet as-
say is in the development stage and is undergoing initial evaluation
of intra- and inter-laboratory reproducibility. The RSMN using Epi-
S. Pfuhler et al. / Regulatory Toxicology and Pharmacology 57 (2010) 315–324 319Derm™ has completed Phase 1 and Phase 2 testing showing excel-
lent reproducibility of coded chemicals (Aardema et al., 2010) and
is now undergoing further intra- and inter-laboratory reproducibil-
ity assessment in Phase 3. These are very promising models to con-
sider incorporating into the in vitro genotoxicity endpoints such as
the MNT and Comet assays as described in the proposed test strat-
egy below.3. Decision trees and testing strategies for genotoxicity
assessment of cosmetics
Results from the COLIPA projects described above, along with
an analysis of other non-animal approaches for assessing genotox-
icity were discussed and used to design the following decision tree
for the safety assessment of cosmetics (see Fig. 1). Because there
are no currently available methods to fully replace the standard
in vivo genotoxicity tests at this time, this decision tree is based
in part on use of non-standard methods. The validity and accep-
tance of such an approach is discussed in chapter 3.3.3.1. Weight of evidence as the basic principle
Perhaps the most important non-animal approach for cosmetic
ingredients (as well as general chemicals/drugs) is to make use of
available data and predicted results for the chemical of interest,
using information on the chemical itself, structural/functional ana-
logues, metabolites, etc. in so-called weight of evidence (WoE)
assessments. WoE can help determine if testing is needed at all,
or help design the most appropriate testing in those cases where
additional testing is required to ﬁll data gaps. WoE is broadly ac-
cepted by legislation and safety assessors as a basic principle in
risk assessment and is explicitly mentioned in European chemicalsPre-Test consi
Analyze all available data/infor
properties, exposure, potenti
metabolism, SAR and read-acro
and carcinogen
Weight of evide
evaluati
Determine if there
information available
the genotoxic risk of
in question. Y
Tier II testing: Follow-up po
Scenarios 1, 2 and 3. (Se
Decide if additional test(s) are ap
if so, which one(s). For guidance
text. The chosen test(s) shou
identified in the W
Perform risk
assessment
Enough evidence to be 
considered genotoxic.
No further testing.
Consider as  low 
(negligible) concern for humans 
based on given exposure.
No (more) follow-up testing.
Results
Yes
* „Result“ refers to a positive or negative outcome of an assay which can
Fig. 1. Schematic representation of the decision makingand cosmetics legislation, e.g. in the current draft of the Recast of
the European Cosmetics directive (EU, 2009); REACh Regulation
(EC) No. 1907/2006, Annex XI, 1.2 (European Commission, 2006);
and in the regulation on classiﬁcation, labelling and packaging of
substances and mixtures (‘CLP regulation’; EU, 2008). The proce-
dure usually implies an expert assessment of the relevance, i.e. sci-
entiﬁc validity or suitability of the purpose of a method or
approach before a decision is taken as to how to weigh individual
pieces of information. Consequently, WoE is equally used in pre-
test considerations as well as for the choice of follow-up tests at la-
ter stages, e.g. when positive results are obtained in Tier I tests, and
to judge whether there is sufﬁcient evidence for the presence or
absence of a genotoxic potential or effect. Elements of WoE, the
practical use in an industrial setting and speciﬁcally for cosmetic
ingredients are described in the following section.
3.2. Elements of WoE
The major sources of information that are used within a WoE
assessment performed prior to testing (see Fig. 1) encompass expo-
sure considerations as well as information on the intrinsic/hazard-
ous properties of the chemical under evaluation:
 Exposure: Most cosmetics involve a cutaneous exposure with
skin providing an effective barrier and metabolic detoxiﬁcation
(Oesch et al., 2007; Eilstein et al., 2009). If there is no systemic
exposure and sufﬁcient information for low/no inherent geno-
toxicity, no further testing may be needed. For chemicals with
limited systemic exposure, a Threshold of Toxicological Concern
(TTC) approach can be used (see below).
 Assessment of structural alerts: Expert systems and databases
such as DEREK, MultiCASE, and ADMEWorks (Hayashi et al.,
2005) and the Vitic database (Lhasa Limited, Leeds, UK) arederations
mation, physico-chemical 
al to use TTC approach, 
ss, available genotoxicity 
icity data 
nce (WoE) 
on
 is “enough”
 to conclude on 
 the compound 
es/No?
sitive results from Tier I.
e text Section 3.4.2)
propriate and sufficient, and 
 see options described in the 
ld address the data gaps 
oE evaluation.
Tier I testing: Perform Ames test 
and in vitro micronucleus test. 3rd
test (HPRT or MLA) may be 
needed to comply with SCCS 
requirements
Positive
results
Results
No
No
 be used in a WoE evaluation
process described in Section 3. For details see text.
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genotoxicity. An example for this and the above bullet point is
high molecular weight chemicals such as polymers which may
lack structural alerts, and exposure through the dermal route
may be negligible. Such chemicals may not need to be tested
for genotoxic properties, as long as impurities or unconverted
monomers are not of concern. The presence of structural alerts
is also a component of the TTC approach described below.
 TTC (Threshold of Toxicological Concern): If very low systemic
exposure to a chemical can be demonstrated, the TTC concept
can be used and genotoxicity testing may not be needed. The
TTC risk assessment tool is based on the principle of establish-
ing a human exposure threshold value for chemicals, below
which there is a very low probability of an appreciable risk to
human health (Kroes et al., 2004). The application of the TTC
approach as a decision tree has been extended to cosmetic
ingredients and impurities (Kroes et al., 2007). The TTC decision
tree starts with the identiﬁcation and evaluation of possible
structural alerts for genotoxicity and high potency carcinoge-
nicity. With the exclusion of high potency genotoxins (e.g.
aﬂatoxin-like compounds, N-nitroso-compounds and azoxy
compounds), a TTC of 0.15 lg/person/day (0.0025 lg/kg body
weight/day) can be used. For substances without structural
alerts that raises concern for potential genotoxicity, higher
thresholds could be used depending e.g. on their structural class
(Cramer Class) and according to the follow-up of the
decision tree (Kroes et al., 2007; Cramer et al., 1978; Munro,
1996, 1999).
 Metabolism: If there is sufﬁcient data from in vivo ADME or
in vitro metabolism studies indicating detoxiﬁcation of the test
compound to non-genotoxic species further testing may not be
necessary. However, if detoxiﬁcation does not occur in the ﬁrst
tissue of contact (e.g. skin), tissues may be exposed to the direct
actions of the chemical before detoxiﬁcation occurs. This has to
be taken into account in the risk assessment. The aromatic
amine 4-amino-2-hydroxytoluene, for example, was shown to
be converted into its N-acetylated metabolite in the skin when
the compound is applied via the dermal route (Goebel et al.,
2009). This metabolite was shown to be non-genotoxic in the
Ames test and the in vitro micronucleus assay in peripheral
human lymphocytes (Pfuhler, S., unpublished data).
 The quality of in vitro and/or in vivo genotoxicity data available
from scientiﬁc literature or previous testing needs to be consid-
ered in an initial assessment. The available studies should be
checked for relevance, compliance with good scientiﬁc practice,
current guidelines, consistency with literature data for the
assay in question, etc.
 If there is reliable evidence of lack of carcinogenicity for the cos-
metic ingredient under evaluation, genotoxicity testing would
not be needed. For instance, carcinogenicity results may be
available from testing of the same ingredient under other regu-
latory regimes, such as the rules governing pharmaceuticals.
This also applies to complex raw materials when there are car-
cinogenicity data on all or some of the constitutive ingredients
available, as is the case for some botanical products.
 Structure–activity-relationship (SAR) and read-across: Informa-
tion on DNA binding, electrophilicity and intended functionality
for the chemical of interest, as well as information on struc-
tural/functional analogues, metabolites, etc. can be used to pre-
dict genotoxicity results. Read-across considerations may be
based on the chemical domain (e.g. using the OECD Application
Toolbox (www.oecd.org)) and when data are available on simi-
lar substances. In some cases, sufﬁcient read-across data on
structurally similar materials will be available and indicate a
low/no probability of genotoxic potential. In other cases, this
information may help to pick the appropriate follow-up test(s). Physiological occurrence: Endogenously occurring substances (in
the human) may be considered to be non-hazardous if the phys-
iological amount is not exceeded. It should be kept in mind that
the route of exposure may have an impact on the concentra-
tions achieved in the tissues of concern and that not all tissues
may be protected equally against reactive chemicals.
 History of safe use: Chemicals used in cosmetics most often have
other uses and in some cases have a long history of safe use.
This information cannot be used as a stand-alone decision-mak-
ing tool because the history of safe use, in the absence of com-
prehensive epidemiological data, does not usually provide
conclusive evidence of the absence of mutagenic or carcino-
genic activity. However, the knowledge that a chemical has
been used safely for years can be used in the WoE approach.
3.3. Tier I in vitro testing
In order to test a cosmetic ingredient for its genotoxic potential,
it is common practice in the cosmetic industry to conduct the
Ames assay and an in vitro MNT or CA assay. Most companies are
using the MNT since it is recommended by the SCCS and recogni-
sed as an excellent tool to detect clastogenic and aneugenic effects
(Kirsch-Volders, 1997; Corvi et al., 2008). The MNT has demon-
strated a very high concordance with the in vitro CA assay (Corvi
et al., 2008; Matsushima et al., 1999; Miller et al., 1997), and is
considered a valid alternative to the CA test (Corvi et al., 2008).
In the ongoing COLIPA genotoxicity program the in vitro MNT is
being used as the mammalian cell test of choice, and initial results
indicate that p53 competent, human cells perform best with re-
gards to speciﬁcity of this assay (see Section 2.3.1).
The participants of the Workshop concluded that a two-test
battery may in most cases be sufﬁcient for the purposes of deci-
sion-making within cosmetics companies. One of the reasons for
this common practice of conducting two in vitro genotoxicity tests
is the high sensitivity of such a battery along with the desire to
maintain the speciﬁcity of the prediction (see Section 2.1 and Ta-
ble 1). However, to comply with the SCCS requirements for testing
of cosmetic ingredients, an in vitro gene mutation assay in mam-
malian cells will be included as a third test. This third test can also
be part of the below described follow-up testing strategy, i.e. when
the Ames test shows positive results.3.4. Decision tree for follow-up assessment of Tier I results (see Fig. 1)
In this section the use of test options which are linked to a spe-
ciﬁc data constellation is described, and some of these options in-
clude methods which are not (yet) formally validated. The WoE
evaluation implies an expert assessment of the scientiﬁc validity
or suitability of a method or approach. In REACh it is stated that
‘‘results obtained from suitable in vitro methods may indicate the
presence of a certain dangerous property or may be important in
relation to a mechanistic understanding, which may be important
for the assessment.” In this context, ‘suitable’ means ‘sufﬁciently
developed’ according to internationally agreed test development
criteria (e.g. ECVAM criteria for entry into pre-validation process).
There has been some debate about the appropriate deﬁnition and
use of the terms ‘‘valid” and ‘‘suitable” (e.g. Balls, 2009; Combes,
2007) and whether these terms can be applied to cosmetics (SCCP,
2007). In general, it seems justiﬁed to include information that has
been generated with methods that have not (yet) undergone for-
mal validation as a part of the overall assessment when it can be
demonstrated that the data are relevant. A positive impact on reg-
ulatory acceptance of such an assessment is expected when trans-
parent criteria, reliable documentation and plausibility of the
scientiﬁc reasoning are provided.
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In this case, to fulﬁl the SCCS requirements (SCCP, 2006a), a
third test, namely a gene mutation assay in mammalian cells, will
be performed. If this assay is also negative this conﬁrms the ab-
sence of a genotoxic hazard for the test item and no further testing
will be needed. If the assay is positive Scenario 1, as described be-
low, should be followed.
3.4.2. Follow up when there are positive Tier I in vitro results
When a conclusion about the genotoxic potential cannot be
drawn from the data generated in Tier I testing and/or the applica-
tion of a WoE approach that takes into consideration all data
including the aspects described in Section 3.2, further testing will
be needed. The different scenarios and testing follow-up options
are described below and summarised in Fig. 1.
The ‘‘options” described below for each of the scenarios in
which positive results may arise are considered the most promis-
ing approaches in light of each respective scenario (outcome of
the Tier I testing), however, the choice of suitable assays may vary
depending on the chemical class and the speciﬁc data
constellation.
3.4.2.1. Scenario 1: In the case that the outcome of the Ames test is
positive and in vitro MNT or CA is negative. There are a number of
common options for the follow-up of this scenario:
Option 1: If not already done in Tier 1, carry out a mammalian
gene mutation assay, that either detects mutations at the hprt
(hypoxanthine–guanine phosphoribosyl transferase) or tk (thymi-
dine kinase) gene locus. Being a mandatory part of the SCCS
requirements (SCCP, 2006a) a mammalian gene mutation assay
will have to be performed in conjunction with options 2–4 also.
The sensitivity of the hprt test is reported to be good (in a sim-
ilar range to the sensitivity of the MLA) for a large number of phar-
maceuticals (Matthews et al., 2006) and is considered to be equally
acceptable as the MLA for assessing gene mutation activity in
mammalian cells (Pfuhler et al., 2007; European Chemicals Agency,
2008). Some safety assessors would consider the hprt gene locus to
be preferred as the third in vitro test, rather than the tk, as the clas-
togenic potential of the substance will have already been evaluated
in the MNT or CA; and avoiding this overlap should usually lower
the MP rate. A negative outcome from an hprt assay, in conjunction
with other data that point towards the lack of relevance of the
Ames positive result for mammalian systems may be sufﬁcient to
address a positive outcome in an Ames assay.
Option 2: Carry out the Syrian hamster embryo (SHE) cell trans-
formation assay. This assay is currently the preferred test because
it is listed in the ‘‘Notes of Guidance for the Testing of Cosmetic
Ingredients” (SCCP, 2006a) and the strategy for testing of oxidative
hair dyes (SCCP, 2006b). This assay measures morphological cell
transformation of primary SHE cells (evident as changes in behav-
iour and growth control of cultured cells occurring in the early
steps of carcinogenesis) and has been reported to have a high pre-
dictivity (80% concordance) of rodent carcinogenicity (LeBoeuf
et al., 1990, 1996) as was recently reviewed by the OECD (OECD,
2007). The review reported the results from tests on 203 organic
chemicals and 61 inorganic chemicals of which 78% of the rodent
organic carcinogens and 94% of the inorganic carcinogens were po-
sitive in the SHE assay. 9% of the carcinogens were not detected by
this assay. This assay is especially useful in a strategy for testing
Ames positive chemicals such as aromatic amines, important com-
ponents of hair dyes, since the SHE assay accurately distinguishes
between carcinogenic and non-carcinogenic aromatic amines 90%
of the time (Kerckaert et al., 1998; Isfort et al., 1996). Unlike other
in vitro assays, this assay detects both genotoxic and non-genotoxic
rodent carcinogens (LeBoeuf et al., 1996; Myhr and Zhang, 2000).
Its high predictivity has resulted in some regulatory authorities(e.g. FDA) requesting this test to be carried out as a follow-up test
for positive outcomes in initial standard test batteries (Bigger,
2003). The SHE assay has been evaluated in an ECVAM pre-valida-
tion exercise and shows good intra- and inter-laboratory reproduc-
ibility resulting in the development of a standard protocol and the
conclusion that, in combination with the extensive database sum-
marized in the OECD DRP31 (OECD, 2007), the assay can be used
for the assessment of carcinogenicity potential (VanParys et al.,
2010). A negative outcome from SHE may be sufﬁcient to address
a positive outcome in an Ames assay.
Other cell transformation assays might also be useful for this
purpose if they can be shown to discriminate between genotoxic
carcinogens and genotoxic non-carcinogens.
Option 3: Carry out the in vivo Comet assay which is integrated
into repeat dose toxicology (RDT) studies without the need of addi-
tional animals (‘‘3R” strategy). The in vivo Comet assay has growing
scientiﬁc acceptance not only as a stand-alone assay but also for
integration into RDT studies (European Chemicals Agency, 2008).
A caveat is that this assay is not currently fully accepted from a sci-
entiﬁc or regulatory viewpoint (Pfuhler et al., 2009). A further
point that should be kept in mind is that, for cosmetic ingredients,
no endpoint-speciﬁc positive control group can be included as the
EU Cosmetics Directive prohibited the use of animals for the pur-
pose of genotoxicity testing in March of 2009, and positive control
animals would not otherwise be needed for the RDT study. This
might prove challenging for the Comet assay as, at this point in
time, not many laboratories have sufﬁcient historical data and
experience to support exclusion of the positive control group. In
addition, the suitability of integration of the Comet assay into
RDT studies is currently under investigation in the pharmaceutical
industry, in conjunction with the revision of the ICH S2 (R1) guide-
line (ICH, 2008). In general the option of integration of genotoxicity
endpoints into RDT studies will only be available for cosmetic
ingredients until 2013 when the ban on these studies comes into
force.
Once further developed, the 3D skin Comet assay could also be a
valid choice for dermally exposed chemicals under scenario 1. As
mentioned earlier, the Comet assay detects a broad spectrum of
DNA damage, including effects that lead to gene mutation and
seems therefore suited to add useful information in case the Ames
test and/or mammalian cell gene mutation test are positive. How-
ever, the assay is still undergoing development (see COLIPA project
in Section 2.3.2) and will be considered for use depending on the
outcome of the ongoing studies.
Option 4: It may be that a threshold mode of action can be envis-
aged for the observed genotoxic effect. Although threshold re-
sponses for genotoxicity and carcinogenicity have been related to
non-DNA-reactive chemicals (epigenetic mechanisms (Fukushima
et al., 2005)), they may also apply to DNA-reactive chemicals (Jen-
kins et al., 2005; Henderson et al., 2000; Doak et al., 2007) despite
other ﬁndings that they are linear in nature (i.e. non-threshold)
(Sanner and Dybing, 2005). This is likely to be due to the fact that
organisms can tolerate low level DNA damage due to protective
mechanisms such as DNA repair (Jenkins et al., 2005; Doak et al.,
2008). Examples of this are the alkylating agents, such as ethyl
methane sulfonate (EMS), for which a threshold has been accepted
in vitro and in vivo (Gocke andMüller, 2009). Although it is not easy
to prove experimentally, if a threshold can be shown to exist as
part of a mode of action approach, the exposure level can be taken
together with the threshold concentration in order to make an
assessment on the risk potential of a chemical (Kirkland et al.,
2007a; Carmichael et al., 2009; Kirsch-Volders et al., 2009). Evi-
dence for thresholds typically requires the conduct of extensive
in vivo tests. In the case of EMS the in vitro assays were able to cor-
rectly predict that it exhibited a threshold in vivo; however, more
examples are needed to be able to judge the reliability of in vitro
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scientiﬁc community should give increased attention in the future
to developing in vitro approaches for the establishment of
thresholds.
3.4.2.2. Scenario 2: In the case that the outcome of the Ames test is
negative and that the outcome of in vitro MNT or CA is positive.
Option 1: Carry out the in vivo MNT by integrating it into RDT
studies without the need for additional animals (‘‘3R” strategy) –
this is the straightforward approach but for cosmetic ingredients
it is only permitted until 2013. The integration of the micronucleus
(MN) endpoint into RDT testing is a long and well established
concept (Wakata et al., 1998; Hayashi et al., 2000, 2007; Hamada
et al., 2001) and is already represented in the current OECD guide-
line, which came into effect in 1997 (OECD TG 474). The fact that
micronuclei can be scored in peripheral blood using ﬂow cytome-
try does simplify this approach, and the above mentioned studies
did show that peripheral blood is equally as reliable as the bone
marrow for measuring micronuclei even in rats that exhibit an efﬁ-
cient splenic ﬁltration function.
The integration of the MNT is also recognised by the draft ICH
S2 (R1) guideline, which states that ‘‘the in vivo genotoxicity assays
can often be integrated into RDT studies when the doses are sufﬁ-
cient” (ICH, 2008). At an ECVAM workshop in June 2008, the possi-
bility to integrate the MNT and Comet assays into RDT studies was
thoroughly discussed and the MNT was considered as scientiﬁcally
credible and therefore ready for use in RDT studies (Pfuhler et al.,
2009). The results of further study by the pharmaceutical industry
were presented at the IWGT meeting in Basel Switzerland in Au-
gust 2009 and led to consensus agreement on integration of MNT
in RDT (Rothfuss, A., unpublished report from the International
Workshop on Genotoxicity Tests (IWGT) in Basle 2009).
Option 2: Another possibility to deal with this data constellation
would be to carry out the RSMN or RS Comet assay. Until more sup-
porting data are generated, the RSMN is not sufﬁcient as a stand-
alone follow-up of a positive result from standard in vitro MNT
or CA tests but will add value to the WoE assessment. The RS Co-
met assay is still undergoing development (see COLIPA project in
Section 2.3.2) and will be considered for use depending on the out-
come of the ongoing studies.
Option 3: Carry out the SHE cell transformation assay. See sce-
nario 1, option 2.
Option 4: Investigate the application of a threshold for the ob-
served genotoxic effect. See scenario 1, option 4.
3.4.2.3. Scenario 3: In the case that the outcomes of the Ames test and
the in vitro MNT or CA are positive. In the case that both tests are
positive, then a combination of assays is needed (see respective op-
tions from scenarios 1 and 2). The choice of assays differs according
to the rates of MPs that are associated with each endpoint; how-
ever, one individual assay will usually not be sufﬁcient to resolve
this data constellation. If the WoE from the in vitro follow-up tests
is not sufﬁcient to come to a conclusion as to the genotoxic poten-
tial of such a chemical, then integration of genotoxicity endpoints
into RDT studies could serve as an option, although only until 2013
for cosmetic ingredients.4. Conclusions
In this paper we provide a framework for genotoxicity assess-
ment of cosmetic ingredients based on common practice within
the industry with an emphasis on non-animal approaches. Fea-
tures of this strategy include (a) an extensive pre-testing evalua-
tion using existing data and exposure considerations, (b) in vitro
screening assays, and (c) validated in vitro genotoxicity tests thatcan be used independently or in combination with a WoE approach
to assess the genotoxic potential of cosmetic ingredients. These
tests are sensitive enough to detect rodent carcinogens; however,
their speciﬁcities are not sufﬁcient to replace fully the in vivo ro-
dent assays. Currently, in the case that an in vitro test battery
shows a positive outcome, in vivo genotoxicity endpoints can be
integrated into RDT studies but will only be carried out on the most
promising/relevant ingredients and only after extensive in vitro
testing. In the near future (2013), in vitro assays will be the only
available tools with which to follow-up after positive outcomes
from initial in vitro testing. Therefore, vigorous efforts are ongoing
to improve existing tests (and reduce MPs) and to develop new
models in order to reduce the high attrition rate of new and poten-
tially safe chemicals.
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